GB2041763A - An inhalor for pulverulent medicinal substances - Google Patents

An inhalor for pulverulent medicinal substances Download PDF

Info

Publication number
GB2041763A
GB2041763A GB8003168A GB8003168A GB2041763A GB 2041763 A GB2041763 A GB 2041763A GB 8003168 A GB8003168 A GB 8003168A GB 8003168 A GB8003168 A GB 8003168A GB 2041763 A GB2041763 A GB 2041763A
Authority
GB
United Kingdom
Prior art keywords
nozzle
chamber
dosing
cavity
inhalator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8003168A
Other versions
GB2041763B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CITTERIO G
Original Assignee
Chiesi P
Citterio G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IT2068879U priority Critical patent/IT7920688V0/en
Application filed by Chiesi P, Citterio G filed Critical Chiesi P
Publication of GB2041763A publication Critical patent/GB2041763A/en
Application granted granted Critical
Publication of GB2041763B publication Critical patent/GB2041763B/en
Application status is Expired legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Abstract

The inhalor for pulverulent medicinal substances combining the function of a dosage feeder comprises a nozzle 1, a chamber 8 for the storage of the medicinal substance which can rotate relatively to the nozzle 1, and a cavity 18, for the collection of successive doses of the medicinal substance, communicating with the nozzle 1. Dosing means 14, 14', 15 are provided on the bottom 10 of the chamber 8 and co-operate with dispensing means 16, 17 operated by the relative rotation between the chamber 8 and the nozzle 1 to pour individual and successive doses of medicinal substance into the cavity 18, for inhaling through the nozzle 1. <IMAGE>

Description

SPECIFICATION An inhalator for medicinal substances This invention relates to an inhalator for pulverulent medicinal substances combining the function of a dosage feeder.

The application of medicinal substances in the form of powders by inhalation is quite important in the treatment of pathological forms. To this end, several types of inhalators are already known for inhalation of powders obtained by breakage of capsules and devices for inhalation of pulverulent medicinal substances are known as well.

However, it was found that this second type of apparatus does not provide the desired results due to the particular structure thereof, difficulty in use and not always providing the current dosage.

It is the object of the present invention to provide an inhalator for pulverulent medicinal substances, which avoids the drawbacks found in conventional devices of this type.

This and further objects of the invention will become apparent to those skilled in the art when considering the following description and claims.

According to our invention an inhalator for pulverulent medicinal substances combining the function of a dosage feeder comprises a nozzle, a chamber for storing the said medicinal substance which can rotate relative to said nozzle, a cavity for the collection of successive doses of said medicinal substance communicating with said nozzle, dosing means for said substance provided on the bottom of said chamber, and dispensing means controlled by said relative rotation between said chamber and nozzle to pour into said cavity individual and successive doses of the medicinal substance withdrawn by said dosing means.

A preferred embodiment of the invention is shown only by way of unrestrictive example in the figures of the accompanying drawings, in which: Figure 1 is a side view of the inhalator as a who!e; Figure 2 is an enlarged sectional view taken along line Il-Il of Figure 1; Figure 3 is an enlarged view according to arrow A of Figure 1; Figure 4 is a sectional view taken along line lV-IV of Figure 2; Figure 5 is a sectional view taken along line V-V of Figure 2; and Figure 6 is an enlarged view according to arrow B of Figure 1.

Referring to the above Figures of the accompanying drawings, the inhalator essentially comprises a nozzle generally designated at 1 which is mounted for free rotation on a main body generally designated at 2.

The nozzle 1 has an opening 3 communicating with an inner space 4 which tapers to a circular hole 5 leading, in turn, to a central conduit 6 which slightly tapers in the opposite direction which respect to the hole 5. The conduit 6 comprises a tubular element 7 arranged axially of the body and free to rotate with respect to the latter. The element 7 is integral with a crown 5' which forms part of the nozzle 1 and defines the hole 5.

The body 2 defines a storage chamber 8 for a pulverulent medicinal substance and advantageously the volume of such a chamber is such as to store an amount of medicinal substance sufficient for a complete treatment cycle. A closure element 9 defines the top of chamber 8, whereas the lower part thereof is defined by a bottom 10 connecting to the wall 11 of chamber 8 through an inclined surface 12 forming with the bottom 10 an annular vertical surface 13.

Two opposing dosing holes 14 and 14' are formed in the bottom 10, each of which has a volume exactly corresponding to one dose of medicament.

At the bottom side the end portion of the tubular element 7 has an integral diaphragm or skirt 15, which is semi-circular and horizontal and bears on the annular surface 13. The skirt is discontinuous for some length substantially corresponding to the length of each of the dosing holes 14, 14' (Figure 4).

The extreme portion of the element 7 has keyed thereto at the bottom of said bottom 10 at 16' a dispensing disc 16 which is provided with a dispensing hole 17 intended for successive registration with the dosing holes 14 and 14', as described in the following.

The lower portion of the body 2 forms a cavity 1 8 communicating with the exterior of the nozzle by two labyrinth-shaped opposing apertures 19 (Figure 6), such a shape being due to the provision of tortous walls 20.

Substantially at the level of the skirt 1 5 and internally of the conduit 6, element 7 is provided with helically extending blades 21. At the level of the dispensing disc 1 6 internally of the body 2 two opposing projections 22 and 22' are provided and are intended to be successively engaged by two tongues 23 formed on the peripheral edge of the dosing disc 16 opposite to the dispensing hole 1 7.

Should the inhalator be of a disposal type, means must be made for breaking the seal when the inhalator is first to be used. These means comprises a breakable small pin 24 which is integral with the body 2. Upon first filling and assembling the inhalator the pin 24 engages in a notch formed peripherally in the dosing disc 16, or also equivalent means located between the nozzle 1 and the body 2.

Prior to initial use, as shown in the Figures of the drawings, the chamber 8 is filled with a sufficient amount of medicament for a complete treatment cycle, the skirt 15 closes the dosing and dispensing holes 140 and 17, now in register, the dosing hole 14 is full with a dose of medicament in register with the discontinuous zone of the skirt 15 and is closed at the bottom by the dispensing disc 16, the small integral pin 24 engages the notch 25 to ensure the integrity of the inhalator, and the tongue 23 engage the notch 22'.

In operation, a user causes relative rotation between the nozzle 1 and the body 2 to take place by gripping the inhalator with one hand at one region 26 of knurling and by the other hand at another level of the knurling 26', so as to rotate the dispensing disc 16 through 1800. This results in breakage of the small pin 24 until further rotation is prevented by engagement of the tongues 23 with the notch 22.

During such a rotation, the dispensing hole 17 is moved into register with the dosing hole 14 and the dose stored in the latter is pored into the cavity 18, from which it can be inhaled through the conduit 6 and the nozzle 1, owing to the air inflow within the chamber 18 through the labyrinth apertures 19 and also owing to the turbulent motion imparted to the medicament by the helical blades 21. During this rotation, said skirt 15 exposes the dosing hole 14', now closed at the bottom by the dispensing disc 1 6, which will thus be filled up with a new dose in readiness for next use.

Claims (10)

1. An inhalator for pulverulent medicinal substances combining the function of a dosage feeder, comprising a nozzle, a storage chamber for said medicinal substance and rotatable relative to said nozzle, a cavity for the collection of successive doses of said medicinal substance communicating with said nozzle, dosing means formed on the bottom of said chamber, and dispensing means controlled by said relative rotation between said chamber and said nozzle to pour into said cavity individual and successive doses of the medicinal substance as withdrawn by said dosing means.
2. An inhalator according to Claim 1, in which said dosing means comprise at least one dosing hole formed on the bottom of said storage chamber, and a diaphragm for communication during said relative rotation said chamber with said at least one dosing hole.
3. An inhalator according to Claim 2, in which said dispensing means comprise a disc provided with at least one dispensing hole communicating with said cavity for registration during said relative rotation with said at least one dosing hole to pour the dose stored therein into said cavity.
4. An inhalator according to Claim 3, in which the nozzle communicates with said cavity through a conduit carrying said diaphragm and said dosing disc, said nozzle being integral with said conduit, whereby a relative rotation between said nozzle and said chamber causes a corresponding relative rotation between said conduit and the bottom of said chamber.
5. An inhalator according to Claim 4, in which said diaphragm rests with its underside on the upper side of the bottom and the disc rests with its upper side on the underside of said bottom.
6. An inhalator according to Claim 1, in which means are provided for indicating the registering position between said dosing and dispensing means.
7. An inhalator according to Claim 1, in which said storage chamber contains an amount of medicinal substance corresponding to the total amount required for a complete treatment cycle, the dispensing capacity of individual dosing means being calculated in accordance with the nature of said medicinal substance.
8. An inhalator according to Claim 7, in which means are provided as a guarantee to be broken upon the first use of said inhalator.
9. An inhalator according to Claim 1, in which said cavity is formed on and opposite to the bottom of said chamber and has labyrinth apertures communicating with the outside, helical blade-shaped means being interposed between said cavity and said nozzle.
10. An inhalator substantially as described herein with reference to and as illustrated in the accompanying drawings.
GB8003168A 1979-02-05 1980-01-30 Inhalor for pulverulent medicinal substances Expired GB2041763B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT2068879U IT7920688V0 (en) 1979-02-05 1979-02-05 Inhaler for pulverulent medicinal substances, with combined metering function.

Publications (2)

Publication Number Publication Date
GB2041763A true GB2041763A (en) 1980-09-17
GB2041763B GB2041763B (en) 1983-08-17

Family

ID=11170583

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8003168A Expired GB2041763B (en) 1979-02-05 1980-01-30 Inhalor for pulverulent medicinal substances

Country Status (5)

Country Link
DE (1) DE8002702U1 (en)
ES (1) ES248348Y (en)
FR (1) FR2447725B3 (en)
GB (1) GB2041763B (en)
IT (1) IT7920688V0 (en)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069715A1 (en) * 1981-07-08 1983-01-12 Aktiebolaget Draco Powder inhalator
GB2144997A (en) * 1981-07-08 1985-03-20 Draco Ab Dosage inhalator
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB2165159A (en) * 1984-10-04 1986-04-09 Orion Yhtymae Oy Dosing device
WO1991012040A1 (en) * 1990-02-16 1991-08-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Powder inhalator
DE4106379A1 (en) * 1990-03-02 1991-09-05 Glaxo Group Ltd Inhalationsgeraet and packaging for this
US5046493A (en) * 1988-02-16 1991-09-10 James Kropkowski Nasal dispenser
WO1991013646A1 (en) * 1990-03-07 1991-09-19 Fisons Plc Medicament inhalation device
EP0451745A1 (en) * 1990-04-12 1991-10-16 CHIESI FARMACEUTICI S.p.A. Device for the administration of powdered medicinal substances
EP0518087A1 (en) * 1991-06-14 1992-12-16 Miat S.P.A. Multi-dose insufflator for medicaments in powder form
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
WO1993009832A1 (en) * 1991-11-12 1993-05-27 Minnesota Mining And Manufacturing Company Inhalation device
US5243970A (en) * 1991-04-15 1993-09-14 Schering Corporation Dosing device for administering metered amounts of powdered medicaments to patients
WO1993021980A1 (en) * 1992-05-05 1993-11-11 Astra Aktiebolag Dosage inhalator with indicating/interrupting means
EP0573128A2 (en) * 1990-07-13 1993-12-08 Innovata Biomed Limited Inhaler
US5301666A (en) * 1991-12-14 1994-04-12 Asta Medica Aktiengesellschaft Powder inhaler
US5394868A (en) * 1992-06-25 1995-03-07 Schering Corporation Inhalation device for powdered medicaments
US5437271A (en) * 1993-04-06 1995-08-01 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5447151A (en) * 1990-10-04 1995-09-05 Valois Powder inhaler with suction actuated locking means
WO1995029723A1 (en) * 1994-05-03 1995-11-09 Transcoject Marketing Gmbh Inhaler
US5469843A (en) * 1991-11-12 1995-11-28 Minnesota Mining And Manufacturing Company Inhalation device
US5533502A (en) * 1993-05-28 1996-07-09 Vortran Medical Technology, Inc. Powder inhaler with aerosolization occurring within each individual powder receptacle
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5615670A (en) * 1990-03-07 1997-04-01 Fisons Plc Powder inhaler with centrifugal force used to meter powder
US5687710A (en) * 1992-12-18 1997-11-18 Schering Corporation Inhaler for powdered medications having spiral deagglomeration chamber
US5975076A (en) * 1993-12-31 1999-11-02 King's College London Dry powder inhalers
EP1291031A1 (en) * 2000-06-12 2003-03-12 Teijin Limited Powder medicine multiple dose administration device
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
EP1283036B1 (en) * 1998-11-13 2008-01-02 Jagotec AG Multidosis dry powder inhaler with powder reservoir
EP1891973A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP1891974A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP1941868A2 (en) 2000-02-28 2008-07-09 PharmaKodex Limited Improvements in or relating to the delivery of oral drugs
WO2008107125A1 (en) 2007-03-02 2008-09-12 Almirall, S.A. New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
US7617822B2 (en) 2003-06-16 2009-11-17 Rijksuniversiteit Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010072354A1 (en) 2008-12-22 2010-07-01 Almirall, S.A. MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
WO2010097172A1 (en) 2009-02-27 2010-09-02 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2263998A1 (en) 2005-05-20 2010-12-22 Almirall S.A. Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012041476A1 (en) 2010-09-30 2012-04-05 Almirall, S.A. Pyridine and isoquinoline derivatives as syk- and jak-kinase inhibitors
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012069202A1 (en) 2010-11-26 2012-05-31 Almirall,S.A. Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
US8205614B2 (en) 1999-09-04 2012-06-26 Innovata Biomed Limited Delivery device
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US8511302B2 (en) 2004-04-24 2013-08-20 Innovata Biomed Limited Dose counter mechanisms for medicament delivery devices
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
WO2014095920A1 (en) 2012-12-18 2014-06-26 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
US8800550B2 (en) 2001-11-23 2014-08-12 Innovata Biomed Limited Medicament delivery assembly
WO2014124757A1 (en) 2013-02-15 2014-08-21 Almirall, S.A. Pyrrolotriazine derivatives as pi3k inhibitors
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
WO2015091285A1 (en) 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
WO2016170009A1 (en) 2015-04-21 2016-10-27 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
WO2016180753A1 (en) * 2015-05-08 2016-11-17 Iconovo Ab Dry powder inhaler
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2017076990A1 (en) 2015-11-05 2017-05-11 Almirall, S.A. Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
USRE46417E1 (en) 1999-07-14 2017-05-30 Almirall, S.A. Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2019030298A1 (en) 2017-08-08 2019-02-14 Almirall, S.A. Novel compounds activating the nrf2 pathway

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280967B6 (en) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalation device
EP0592601B1 (en) * 1991-06-26 1996-05-08 Schering Corporation Inhalation device for powdered medicaments
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Sputtering for a powder mixture and method for dry powder inhalers

Cited By (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069715A1 (en) * 1981-07-08 1983-01-12 Aktiebolaget Draco Powder inhalator
GB2144997A (en) * 1981-07-08 1985-03-20 Draco Ab Dosage inhalator
US4524769A (en) * 1981-07-08 1985-06-25 Aktiebolaget Draco Dosage inhalator
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB2165159A (en) * 1984-10-04 1986-04-09 Orion Yhtymae Oy Dosing device
DE3535561A1 (en) * 1984-10-04 1986-05-22 Orion Yhtymae Oy Device for the metered delivery of a medicinal substance
US5046493A (en) * 1988-02-16 1991-09-10 James Kropkowski Nasal dispenser
US5628307A (en) * 1989-05-31 1997-05-13 Fisons Plc Medicament inhalation device and formulation
US5538999A (en) * 1989-05-31 1996-07-23 Fisons Plc Medicament inhalation device and formulation
US5341800A (en) * 1989-05-31 1994-08-30 Fisons Plc Medicament inhalation device and formulation
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
WO1991012040A1 (en) * 1990-02-16 1991-08-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Powder inhalator
US5320714A (en) * 1990-02-16 1994-06-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Powder inhalator
DE4106379A1 (en) * 1990-03-02 1991-09-05 Glaxo Group Ltd Inhalationsgeraet and packaging for this
US6032666A (en) * 1990-03-02 2000-03-07 Glaxo Group Limited Inhalation device
DE4106379C2 (en) * 1990-03-02 1998-09-24 Glaxo Group Ltd Inhaler and medication pack this
WO1991013646A1 (en) * 1990-03-07 1991-09-19 Fisons Plc Medicament inhalation device
US5615670A (en) * 1990-03-07 1997-04-01 Fisons Plc Powder inhaler with centrifugal force used to meter powder
US5351683A (en) * 1990-04-12 1994-10-04 Chiesi Farmaceutici S.P.A. Device for the administration of powdered medicinal substances
EP0451745A1 (en) * 1990-04-12 1991-10-16 CHIESI FARMACEUTICI S.p.A. Device for the administration of powdered medicinal substances
EP0573128A3 (en) * 1990-07-13 1994-03-02 Innovata Biomed Ltd
EP0573128A2 (en) * 1990-07-13 1993-12-08 Innovata Biomed Limited Inhaler
US5657748A (en) * 1990-07-13 1997-08-19 Innovata Biomed Limited Powder inhaler with frusto-conical metering surface having dose indentations
US5437270A (en) * 1990-07-13 1995-08-01 Innovata Biomed Limited Powder inhaler having a multi-positioned metering cup
US5447151A (en) * 1990-10-04 1995-09-05 Valois Powder inhaler with suction actuated locking means
US5243970A (en) * 1991-04-15 1993-09-14 Schering Corporation Dosing device for administering metered amounts of powdered medicaments to patients
EP0518087A1 (en) * 1991-06-14 1992-12-16 Miat S.P.A. Multi-dose insufflator for medicaments in powder form
WO1993009832A1 (en) * 1991-11-12 1993-05-27 Minnesota Mining And Manufacturing Company Inhalation device
US5469843A (en) * 1991-11-12 1995-11-28 Minnesota Mining And Manufacturing Company Inhalation device
US5301666A (en) * 1991-12-14 1994-04-12 Asta Medica Aktiengesellschaft Powder inhaler
AU669708B2 (en) * 1992-05-05 1996-06-20 Astra Aktiebolag Dosage inhalator with indicating/interrupting means
US5549101A (en) * 1992-05-05 1996-08-27 Astra Aktiebolag Dosage inhalator with indicating/interrupting means
WO1993021980A1 (en) * 1992-05-05 1993-11-11 Astra Aktiebolag Dosage inhalator with indicating/interrupting means
US5394868A (en) * 1992-06-25 1995-03-07 Schering Corporation Inhalation device for powdered medicaments
US5687710A (en) * 1992-12-18 1997-11-18 Schering Corporation Inhaler for powdered medications having spiral deagglomeration chamber
US5829434A (en) * 1992-12-18 1998-11-03 Schering Corporation Inhaler for powdered medications
US5740792A (en) * 1992-12-18 1998-04-21 Schering Corporation Inhaler for powdered medications with gear-teeth counter assembly
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5437271A (en) * 1993-04-06 1995-08-01 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
US5533502A (en) * 1993-05-28 1996-07-09 Vortran Medical Technology, Inc. Powder inhaler with aerosolization occurring within each individual powder receptacle
US5975076A (en) * 1993-12-31 1999-11-02 King's College London Dry powder inhalers
WO1995029723A1 (en) * 1994-05-03 1995-11-09 Transcoject Marketing Gmbh Inhaler
US5738865A (en) * 1995-04-07 1998-04-14 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US7172766B2 (en) 1995-04-07 2007-02-06 Penwest Pharmaceuticals Company Controlled release insufflation carrier for medicaments
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6387394B1 (en) 1995-04-07 2002-05-14 Penwest Pharmaceuticals Co. Controlled release insufflation carrier for medicaments
EP1283036B1 (en) * 1998-11-13 2008-01-02 Jagotec AG Multidosis dry powder inhaler with powder reservoir
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
USRE46417E1 (en) 1999-07-14 2017-05-30 Almirall, S.A. Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US8205614B2 (en) 1999-09-04 2012-06-26 Innovata Biomed Limited Delivery device
EP1941868A2 (en) 2000-02-28 2008-07-09 PharmaKodex Limited Improvements in or relating to the delivery of oral drugs
EP1291031A1 (en) * 2000-06-12 2003-03-12 Teijin Limited Powder medicine multiple dose administration device
EP1291031A4 (en) * 2000-06-12 2004-12-15 Teijin Ltd Powder medicine multiple dose administration device
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
US8800550B2 (en) 2001-11-23 2014-08-12 Innovata Biomed Limited Medicament delivery assembly
US7617822B2 (en) 2003-06-16 2009-11-17 Rijksuniversiteit Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
US8511302B2 (en) 2004-04-24 2013-08-20 Innovata Biomed Limited Dose counter mechanisms for medicament delivery devices
EP2774623A1 (en) 2004-05-31 2014-09-10 Almirall S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP1891973A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP1891974A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP2774622A1 (en) 2004-05-31 2014-09-10 Almirall, S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2002843A2 (en) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2138188A1 (en) 2004-05-31 2009-12-30 Almirall, S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2002844A2 (en) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinations comprising antimuscarininc agents and beta-adrenergic agonists
EP2002845A2 (en) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
EP2292267A2 (en) 2004-05-31 2011-03-09 Almirall S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP1905451A1 (en) 2004-05-31 2008-04-02 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
EP2319538A2 (en) 2004-05-31 2011-05-11 Almirall S.A. Combinations combrising antimuscarinic agents and corticosteroids
US7964615B2 (en) 2005-05-20 2011-06-21 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
EP2263998A1 (en) 2005-05-20 2010-12-22 Almirall S.A. Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
US8420669B2 (en) 2005-05-20 2013-04-16 Laboratories Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor
US8242177B2 (en) 2005-05-20 2012-08-14 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
WO2008107125A1 (en) 2007-03-02 2008-09-12 Almirall, S.A. New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2954891A1 (en) 2008-03-13 2015-12-16 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma
EP2946769A1 (en) 2008-03-13 2015-11-25 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2946768A1 (en) 2008-03-13 2015-11-25 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2954890A1 (en) 2008-03-13 2015-12-16 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2954889A1 (en) 2008-03-13 2015-12-16 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
US8563731B2 (en) 2008-12-22 2013-10-22 Almirall, S.A. Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
WO2010072354A1 (en) 2008-12-22 2010-07-01 Almirall, S.A. MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
WO2010094484A1 (en) 2009-02-18 2010-08-26 Almirall, S.A. 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino}-l-hydroxyethyl) -8-hydroxyquin olin-2 (1h)-one and its use in the treatment of pulmonary diseases
WO2010094483A1 (en) 2009-02-18 2010-08-26 Almirall, S.A. 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for the treatment of lung function
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
WO2010097172A1 (en) 2009-02-27 2010-09-02 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
WO2011057757A1 (en) 2009-11-11 2011-05-19 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2011141180A1 (en) 2010-05-13 2011-11-17 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012041476A1 (en) 2010-09-30 2012-04-05 Almirall, S.A. Pyridine and isoquinoline derivatives as syk- and jak-kinase inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012069175A1 (en) 2010-11-25 2012-05-31 Almirall, S.A. New pyrazole derivatives having crth2 antagonistic behaviour
WO2012069202A1 (en) 2010-11-26 2012-05-31 Almirall,S.A. Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2012146667A1 (en) 2011-04-29 2012-11-01 Almirall, S.A. Imidazopyridine derivatives as pi3k inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
WO2012160030A1 (en) 2011-05-25 2012-11-29 Almirall, S.A. Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
WO2013010880A1 (en) 2011-07-18 2013-01-24 Almirall, S.A. New crth2 antagonists
WO2013010881A1 (en) 2011-07-18 2013-01-24 Almirall, S.A. NEW CRTh2 ANTAGONISTS
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013017461A1 (en) 2011-08-01 2013-02-07 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2013068554A1 (en) 2011-11-11 2013-05-16 Almirall, S.A. New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
WO2013068552A1 (en) 2011-11-11 2013-05-16 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
US9346759B2 (en) 2012-03-20 2016-05-24 Almirall, S.A. Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
WO2013139712A1 (en) 2012-03-20 2013-09-26 Almirall, S.A. NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2013149959A1 (en) 2012-04-02 2013-10-10 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
WO2013175013A1 (en) 2012-05-25 2013-11-28 Almirall, S.A. Novel dosage and formulation
WO2013178742A1 (en) 2012-05-31 2013-12-05 Almirall, S.A. Novel dosage form and formulation of abediterol
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
WO2014095920A1 (en) 2012-12-18 2014-06-26 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
WO2014124757A1 (en) 2013-02-15 2014-08-21 Almirall, S.A. Pyrrolotriazine derivatives as pi3k inhibitors
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
WO2015091287A1 (en) 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
WO2015091285A1 (en) 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
WO2016170009A1 (en) 2015-04-21 2016-10-27 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
WO2016180753A1 (en) * 2015-05-08 2016-11-17 Iconovo Ab Dry powder inhaler
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2017076990A1 (en) 2015-11-05 2017-05-11 Almirall, S.A. Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
WO2019030298A1 (en) 2017-08-08 2019-02-14 Almirall, S.A. Novel compounds activating the nrf2 pathway

Also Published As

Publication number Publication date
DE8002702U1 (en) 1980-05-29
GB2041763B (en) 1983-08-17
FR2447725B3 (en) 1981-01-02
IT7920688V0 (en) 1979-02-05
ES248348Y (en) 1981-02-16
FR2447725A3 (en) 1980-08-29
ES248348U (en) 1980-05-01

Similar Documents

Publication Publication Date Title
US3506008A (en) Medical applicator
US3239145A (en) Dispensing container for air treating gel
RU2111020C1 (en) Powdered drug inhaler
US4282986A (en) Method for discharge of quantities of fluid or semi-fluid substances from a container
CN1997418B (en) Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
KR100390480B1 (en) inspirator
RU2075977C1 (en) Inhalator to be used together with medicinal block
JP3209539B2 (en) Delivery device of the powder drug
AU2001270112B2 (en) Pre-metered dose magazine for breath-actuated dry powder inhaler
US3908654A (en) Dispensing package for a dry biological and a liquid diluent
US4884565A (en) Insufflator for the administration of drugs in the form of a powder pre-dosed into opercola
EP1499376B1 (en) Medicament dispenser
EP0632734B1 (en) Powder jet dispenser for medicament inhalation therapies
KR100218816B1 (en) Powder inhaler
RU2097069C1 (en) Device for applying inhalation procedures
EP0406893B1 (en) Medicament inhalation device
EP0271029B1 (en) Inhaler
EP0129985B1 (en) Inhalation device
EP0977612B1 (en) Applicator for semi-solid medications
CA2141465C (en) Medicament inhaler and method
FI71487C (en) Inhalator.
AU701843B2 (en) Removable precision dosating unit for ultrasonic atomizer device
KR0128232B1 (en) Medicament dispensing device
FI104236B (en) An inhalation
US5857457A (en) Powder inhaler with remnant mover and chamber

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19930130